ANTIPODES PARTNERS Ltd Purchases Shares of 185,698 Genmab A/S (NASDAQ:GMAB)

ANTIPODES PARTNERS Ltd purchased a new position in Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 185,698 shares of the company's stock, valued at approximately $5,912,000.

A number of other institutional investors also recently bought and sold shares of the stock. Park Place Capital Corp increased its stake in Genmab A/S by 12.3% in the fourth quarter. Park Place Capital Corp now owns 4,891 shares of the company's stock worth $156,000 after purchasing an additional 535 shares during the period. International Assets Investment Management LLC purchased a new stake in Genmab A/S in the fourth quarter worth $393,000. China Universal Asset Management Co. Ltd. increased its stake in Genmab A/S by 350.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company's stock worth $154,000 after purchasing an additional 3,770 shares during the period. Legacy Wealth Asset Management LLC increased its stake in Genmab A/S by 19.0% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 35,092 shares of the company's stock worth $1,117,000 after purchasing an additional 5,596 shares during the period. Finally, Exchange Traded Concepts LLC increased its stake in Genmab A/S by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 3,691 shares of the company's stock worth $118,000 after purchasing an additional 936 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GMAB. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday. Morgan Stanley restated an "underweight" rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Citigroup lowered Genmab A/S from a "neutral" rating to a "sell" rating in a research note on Monday, January 22nd. Truist Financial restated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research note on Tuesday, March 26th. Finally, BMO Capital Markets upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $46.00 to $48.00 in a research note on Friday, February 23rd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $48.50.

Genmab A/S Price Performance

NASDAQ GMAB traded up $0.11 during trading on Friday, hitting $29.76. The company's stock had a trading volume of 237,451 shares, compared to its average volume of 626,695. The company has a market cap of $19.66 billion, a PE ratio of 30.89, a P/E/G ratio of 1.37 and a beta of 0.99. The business's 50 day simple moving average is $29.06 and its 200-day simple moving average is $30.82. Genmab A/S has a fifty-two week low of $26.32 and a fifty-two week high of $42.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.02. The business had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. Analysts expect that Genmab A/S will post 1.09 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.